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Abstract 
Iron deficiency anemia is a common problem world-wide, and doctors from all specialties 
need to be competent in its treatment.  While most patients respond well to oral iron 
preparations, a substantial minority have side effects which make them adhere poorly to their 
treatment.  For oral iron-intolerant patients, those responding poorly despite good adherence, 
and those with severe and/or symptomatic anemia, intravenous iron is an excellent alternative.  
It is, however, more expensive and carries a very small but potentially life-threatening risk of 
severe infusion-related hypersensitivity reactions.  After outlining the main features of iron 
metabolism, in this review we compare the indications for therapy with oral and intravenous 
iron, and then focus on how to maximize the efficacy and safety of the two different routes. 
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Introduction  
Anemia is common in all populations worldwide and is frequently due to iron deficiency.  In 
developed countries, the prevalence of iron deficiency anemia (IDA) is 2-5% in adult men and 
post-menopausal women   and about 10% in women of child-bearing age; it is much more 
common in hospitalized patients [1, 2, 3]. 
 
Iron deficiency occurs when iron losses exceed its intestinal absorption. This happens in 
patients with decreased iron intake, malabsorption of iron, increased demand for iron or 
through ongoing iron loss.  In the Western world, while IDA is often multifactorial, 
menstruation is the commonest single cause. Reduced dietary intake of iron (vegetarians and 
the elderly being particularly at risk), bleeding from the gastrointestinal tract (for example due 
to neoplasia or use of aspirin or non-steroidal anti-inflammatory drugs), malabsorption 
(particularly in coeliac disease), pregnancy and blood donation are other frequent causes [3, 
4]. 
 
IDA is associated with worsened quality of life, impaired physical and cognitive performance 
[2, 5], and in hospitalized patients, longer length of hospital stay and poorer clinical outcomes 
[1, 6]. It also increases the likelihood of patients receiving blood transfusions with their 
attendant risks [1].  Effective treatment of patients with IDA is therefore extremely 
worthwhile. 
 
The aims of this article, which is directed primarily at generalists, are to outline the relevant 
features of iron metabolism, to summarize the indications for treatment of IDA and to 
compare the advantages and disadvantages of treatment with oral and intravenous iron.  We 
shall then focus particularly on practical aspects of treatment with iron.  Topics which we 
shall not cover include investigation of the cause of IDA (for guidance see reference [3]) and 
use of blood transfusion.   We shall also omit mention of therapy with erythropoietin, as this 
is a specialist treatment restricted primarily to patients with chronic kidney disease or having 
cancer chemotherapy. 
 
Iron Metabolism 
As a background to our focus on management of IDA, we provide below a brief overview of 
iron metabolism (for a comprehensive recent review, see reference [7]). 
 
 
Iron absorption and turnover 
The human body contains 30-40mg/kg body weight of iron. It is mostly contained in 
haemoglobin (Hb), ferritin and other heme and non-heme proteins. Iron is an essential 
element, being a constituent of a range of enzymes involved in redox reactions and oxygen 
delivery.  Red blood cells have the highest demand for iron of all cells. 
 
A normal Western diet provides 10-15mg of iron daily, of which only about 10% is absorbed 
(1-2mg each day).  Iron absorption occurs only in the duodenum and jejunum. Most iron 
ingested in food is in the ferric form (Fe3+) and requires reduction to the ferrous form (Fe2+) 
for absorption across the mucosal barrier.  Factors influencing iron uptake in the gut include: 
the form of iron and its redox state within food, the pH of the intestinal lumen, the presence or 
absence of chelating agents in food (e.g. phytate or oxalate) and the expression levels of 
several iron transporters in enterocytes. 
 
Within enterocytes, iron is either stored as ferritin or is actively exported as ferrous iron by 
the transporter protein ferroportin, into the plasma.  The ferrous iron is then oxidized back to 
ferric iron which can bind to the circulating carrier protein, transferrin.  
 
As the amount of iron absorbed is not sufficient to cover the requirements of erythropoiesis, 
iron is recycled. Heme complexes are degraded in the liver and spleen by cells of the 
monocyte-macrophage system.  These reticulo-endothelial cells and hepatocytes store the iron 
released from heme complexes as ferritin and release it into the plasma, again through 
ferroportin, when serum iron levels drop [8].  
 
Role of hepcidin 
There is no excretion method for iron and therefore iron homeostasis is regulated by its 
absorption into and release from the macrophage and hepatocyte iron stores.  Hepcidin is a 
peptide hormone synthesized in hepatocytes (for recent review, see reference [8]).  It regulates 
plasma iron concentrations by binding with ferroportin and causing degradation of the ligand-
receptor complex.  By causing loss of ferroportin from cell membranes, high levels of 
hepcidin reduce both iron absorption from the gut and also its release from macrophages and 
hepatocytes into plasma. 
 
Serum hepcidin levels increase in response to increased plasma iron levels and prevent iron 
overload.  This regulation is important because, as in hemochromatosis, excessive tissue iron 
can cause widespread organ damage, probably as a result of generation of free radicals.  
Hepcidin is also an acute phase reactant and its production is increased in inflammatory 
disease, infection and cancer by interleukin-6 and other cytokines. Affected patients typically 
show the blood indices of the anemia of chronic disease (see Table 1 below). Conversely, in 
conditions such as iron deficiency, hemorrhage, hemolysis and treatment with erythropoietin, 
a decrease in hepcidin levels occurs, so that maximal iron is made available for erythropoiesis 
[8]. 
 
Definition of Iron Deficiency Anemia 
The World Health Organisation (WHO) defines anemia as a hemoglobin concentration below 
13g/dl in adult men and below 12g/dl in non-pregnant adult women (see Table 2) [2]. 
 
Before considering giving oral or intravenous iron to patients with anemia, it is essential, in 
order to avoid the risk of iron overload, to confirm that they are indeed iron deficient, and do 
not have the anemia of chronic disease (Table 1).  Classically, patients with IDA have low 
serum iron, ferritin and transferrin saturation, with high serum transferrin and total iron-
binding capacity.  In many instances, however, the anemia is of mixed type and a clear 
distinction between the two is difficult to make.  
 
Management of iron deficiency anemia 
An early step in the management of IDA, which can of course be undertaken at the same time 
as treatment of the anemia itself, is to find and treat the underlying cause. That process is 
beyond the scope of this review (see instead reference [3]).  
 Iron therapy is used to replenish iron stores and restore hemoglobin concentrations to 
normal, thereby preventing and treating symptoms arising from IDA [3,5].  Potential 
benefits of iron replacement include improved quality of life, physical performance, 
thermoregulation, cognitive function and immune function [5,10,11].   Restless leg 
syndrome may also respond to iron replenishment [10,12]. 
 In practice, the commonest indications for therapy are anemia (Hb < 12g/dl (non-
pregnant women), Hb < 13g/dl (men)) and iron deficiency without anemia, the latter 
especially if the primary cause is on-going (eg chronic blood loss, pregnancy or in 
patients with concurrent diseases such as chronic renal failure, inflammatory bowel 
disease or cancer requiring chemotherapy) [5].  
 
Oral or intravenous iron? 
When deciding on the most appropriate therapy for patients with IDA there are several factors 
to take into account. 
 
Availability, patient adherence to treatment 
Oral iron salts are the most readily available way of replacing iron. Taken once or twice a day 
in tablet form, they are the first line treatment for most indications [4,13]. Intravenous iron, in 
contrast, needs to be administered by trained staff in a centre where resuscitation facilities are 
immediately available due to the risk of severe hypersensitivity reactions (see below) [14,15]. 
High molecular weight dextran parenteral iron preparations are no longer available, and there 
is also only a very limited place now for intramuscular iron because of its potential side 
effects (brown staining of subcutaneous tissues, local pain, sterile abscess, atrophy and 
fibrosis) and because of the ready availability of iv iron. Non-adherence to treatment with oral 
iron is common, particularly in patients with iron intolerance (see below) but this is not a 
problem with iv iron. 
 
Efficacy 
Both routes of administration are adept at raising iron stores and hemoglobin concentrations. 
The initial rise in hemoglobin tends to be faster with iv iron, but at about 6 weeks the rise is 
similar to that seen with oral therapy [16,17,18].   Accordingly, in patients with severe iron 
deficiency anemia or in those who are symptomatic from their anemia, the iv route may be 
preferred.  Intravenous iron may also be preferable in patients with malabsorption syndromes 
and in those with chronic inflammatory diseases such as inflammatory bowel disease. In such 
cases a raised serum hepcidin may, as suggested above, inhibit absorption of oral iron [5,9]. 
 
Although there is not yet a routinely available assay for hepcidin, it is possible from what is 
known about its actions (see above) that in the future, a pre-treatment hepcidin measurement 
could be used to predict response to iron therapy and/or the optimum route of iron 
administration. The oral route might be most effective when pre-treatment hepcidin levels are 
low, and the intravenous route more effective when they are raised. 
 
Side effects 
Gastro-intestinal symptoms, which occur in up to 30% of people taking oral iron, include 
nausea, flatulence, abdominal pain, constipation and diarrhoea. The clinical impression that 
these side-effects are dose-related has not been confirmed in a recent meta-analysis [19]. Dark 
coloured stools simply reflect the presence of unabsorbed iron and are of no clinical 
significance. 
 
The side effects of iv iron are diverse and occur acutely during or shortly after infusions (see 
below, Fig 1). The risks of severe reactions are now much lower than they were when the now 
obsolete high molecular weight dextran preparations were used, but it has been suggested that 
fatal hypersensitivity reactions still occur during infusions in about 1 in every 5 million doses 
of iv iron [20,21]. 
 Iron overload is a rare but potentially serious side-effect in patients mistakenly given long 
courses of iron by either route when they are not actually iron deficient.  Theoretical but 
unsubstantiated further risks of oral iron include free radical-induced gastrointestinal 
inflammation, changes in gut microbiota and even neoplasia [22,23,24,25]. Conversely, 
after iv iron they include endothelial damage and enhanced atherosclerosis mediated by 
intravascular oxidant stress [26], and a predisposition to infection resulting from iron-
mediated cellular immune dysfunction and stimulation of bacterial growth [25,27]. 
Cost 
The cost of oral iron salts varies between preparations but is very low (about 15-45 euros per 
3 month course depending on dose and formulation prescribed).   In contrast, the prescribing 
costs of iv iron preparations, depending on how much elemental iron is needed to replace iron 
stores, range from about 120-500 euros.  The costs of iron infusions must also take into 
account those of its administration by trained nursing staff in a medically supervised 
environment.  
 
Treatment of IDA with oral iron: practical guidance. 
Oral iron replacement therapy with gradual replenishment of iron stores and restoration of 
hemoglobin is the preferred first line treatment for most patients with IDA [4,13] (Fig 2).  
 
Dosage 
The dose of oral iron for IDA should be 30-80mg elemental iron daily, given for 3-6 months, 
and for longer if the cause of iron deficiency is on-going.  Depending on the cause of the IDA, 
hemoglobin concentration should rise by 0.5-1g/dl (5-10 g/litre) per week [4]. 
 
Administration of oral iron 
Oral ferrous salts are the treatment of choice as ferric salts are less well absorbed.   Selection 
of preparation is often decided by cost.  Although iron preparations are best absorbed when 
the patient has not eaten, they can be taken after food to reduce gastro-intestinal side-effects.  
 
There is little evidence to support the recommendation that patients should take vitamin C or 
orange juice to improve iron absorption though the advice is still given [2,3]. It is also advised 
that, before taking iron tablets, patients avoid eating food high in phytates, phosphates or 
tannates (eg cereals, beans) each of which can reduce the absorption of iron [2,7].  Proton 
pump inhibitors should also be avoided if possible, as they reduce production of gastric acid 
which normally helps promote iron absorption by converting the ferric to the ferrous salt. 
 
Management of side-effects 
The gastro-intestinal side effects described above should be taken seriously as even mild 
symptoms may reduce adherence to oral iron supplementation. There is limited evidence to 
suggest that switching to an alternative oral product can reduce side effects [28]. Despite the 
lack of supportive meta-analytic data [19], a dose reduction is sometimes effective and, 
because of the saturability of intestinal iron absorption, can be equally efficacious in 
replenishing iron stores [29,30,31]. 
 
Modified-release preparations of iron are licensed for once-daily dosage, but have no proven 
therapeutic advantage over conventional formulations. Contrary to some reports [28], meta-
analysis suggests that they are no better tolerated than standard formulations [19].  
Furthermore, it may be advisable to avoid slow-release preparations in patients with Crohn's 
disease because of a risk that they impact upstream of small bowel strictures [32]. 
 
Several new formulations of oral iron are the focus of clinical trials and show promise in 
relation to efficacy and tolerability [33,34] but they are not yet routinely available. 
 
Monitoring of response 
The response to oral iron should be assessed by measurement of serum hemoglobin 
concentration, ferritin and/or transferrin saturation after 6-12 weeks (Fig 2).  In patients in 
whom these indices fail to respond adequately, the physician should check on adherence to 
the medication and consider a switch to iv iron. 
 
Treatment of IDA with intravenous iron: practical guidance. 
 
Indications 
It follows from what has been discussed above that iv is preferable to oral iron in the 
following situations: 
• When oral iron is not tolerated or is ineffective in raising or in maintaining 
hemoglobin concentration 
• When hemoglobin is  <10g/dl (depends on clinical setting) 
• When anemia is symptomatic 
• In chronic inflammatory disease, chronic renal failure, chemotherapy-induced anemia, 
malabsorption and intestinal failure 
• To avoid non-urgent blood transfusions 
 
Selection and dosing of iv iron  
The formulations of iv iron now available in Europe are sodium ferric gluconate (Ferrlecit), 
iron sucrose (Venofer), iron (III)-hydroxide dextran complex (Cosmofer), ferric 
carboxymaltose (Ferinject) and iron (III) isomaltoside 1000 (Monofer). The European 
Medicines Agency (EMA) has recently reported that they were unable to differentiate 
between these products in relation to the risk of severe hypersensitivity reactions [14]. The 
choice of product therefore depends on factors such as cost, convenience to the patient and the 
indication for the treatment [35]. The dosing regimen used (e.g. dose of iron, duration of 
infusion, single dose or multiple infusions) varies with each preparation, and must be applied 
in strict accordance with the Summary of Product Characteristics (SmPC) of each individual 
product. In many centres, ferric carboxymaltose (Ferinject) and iron isomaltoside 1000 
(Monofer) have become widely used as first-line infusions, as they offer the option of rapid 
infusion of a high dose of iron (eg up to 1000 mg in 15 minutes for a man weighing >50kg).   
The total dose of iron needed to be given to replete a patient's iron stores is based on the 
patient’s Hb and body weight and can be calculated using either the Ganzoni formula [36] or 
a Simplified Method [37]. 
 
The Ganzoni formula calculates the total iron deficit requiring intravenous replacement as:  
Body weight [kg] x (Target Hb – Actual Hb) [g/l] x 0.24 + iron stores [mg], where the iron 
stores for a patient >35kg are assumed to be 500mg.  In contrast, the Simplified Method, 
derived initially from a trial using ferric carboxymaltose in patients with inflammatory bowel 
disease [37] allows calculation of the dose of iron needed from the patient’s hemoglobin 
concentration and weight (Table 3). 
 
The response to iv iron should be determined by monitoring the serum hemoglobin 
concentration, transferrin saturation and/or ferritin levels at about 6 weeks after infusion (Fig 
2).   Oral iron is not required after iv iron if the total iron deficit has been corrected. 
 
Side-effects and terminology 
As indicated above, acute side-effects during iron infusions are rare but can be life-
threatening.  Current nomenclature relating to adverse reactions to iv drugs in general is 
confusing and inconsistent.  As elsewhere [15], we find it simplest to refer to all acute 
reactions to iv iron as hypersensitivity reactions (HSRs), sub-dividing them into mild, 
moderate or severe/life-threatening, depending on their clinical presentation (Fig 1).  As 
suggested by the World Allergy Organisation [38], we reserve the term "anaphylaxis" for 
severe HSRs, irrespective of pathogenesis, and avoid the ill-defined term "anaphylactoid". 
This approach is rational insofar as there is little or no evidence that acute reactions to iv iron 
are IgE-mediated.  Indeed, their commonest mechanism is probably complement activation-
related pseudo-allergy (CARPA) evoked by infusion of nanoparticles [39,40]. 
 
Reducing risks of side-effects 
As already mentioned, in 2013 the EMA published a report of their 2-year investigation of the 
adverse drug reactions to all iv iron drugs available in Europe [14]. Their main conclusions 
are outlined below, and should be applied in all settings where iron infusions are given. 
• All iv iron preparations carry a small risk of reactions which can be life-threatening  
• The benefits of iv iron outweigh the risks when oral iron is inappropriate 
• iv iron should be given only where trained staff and resuscitation available  
• A test dose is not needed (as it can give false reassurance about the safety of the 
subsequent infusion) 
• Patients should be monitored during and for > 30 minutes after the infusion  
• All iv iron is contraindicated in patients with known serious HSR to any iv iron 
product  
• iv iron should never be given in the first trimester of pregnancy 
• Special care should be taken if giving iv iron to patients with known allergies 
(including drug allergies) or severe atopy 
 
In practice, minimising the risk of HSRs in patients to be given iv iron involves five main 
considerations:  
•  Patients at particularly high risk of HSRs should be identified.  These include those who 
have had a previous reaction to iv iron, who are given iv infusion too fast, or who have a 
history of other drug or other allergies.  There is an increased risk also in patients with 
severe asthma or eczema, systemic mastocytosis, severe respiratory or cardiac disease and 
in the elderly.  Treatment with beta-blockers or angiotensin converting enzyme (ACE) 
inhibitors can worsen HSRs if they occur, and, as pointed out by the EMA (see above), iv 
iron is strictly contra-indicated in early pregnancy because of the potential for acute 
adverse effects on the foetus. 
• Iron infusions should be given only in appropriately staffed sites equipped with 
resuscitation facilities. If iv iron is to be given outside hospital, there should be 
arrangements in place for immediate treat-and-transfer to an intensive care facility in the 
event of a severe reaction. EMA states that iv iron should not be given in patients’ homes 
[14]. 
• If not given by a doctor, iv iron should be administered by nursing staff with immediate 
access to on-site medical help in the event of an adverse reaction.  All staff should have 
regular training in management of iv infusions and HSRs.  The nurse administering the 
iron infusion should be in the infusion area and easily accessible by the patient throughout 
its course, as HSRs can develop rapidly.   
• The patient should be provided with information about the risk of an HSR before the iron 
infusion; the relevant symptoms should be described, with advice that the patient tells the 
nurse administering the infusion immediately if any occur.  
• The final steps involved in reducing the risks of HSRs to iv iron relate to the infusion 
itself. 
o If the patient has previously had a severe HSR to any iv iron preparation, he/she 
should never again be given iv iron.  In the event of a previously mild HSR to iv iron, 
a different iv iron product should be given very cautiously.   
o Before starting any infusion, base-line clinical observations should be undertaken, 
including pulse, blood pressure, respiratory rate and oxygen saturation.   
o No test dose is necessary.  
o The infusion should be started at 50% of the recommended infusion rate (10% if the 
patient has been identified as being at high risk - see above), accelerating after 15 
minutes to the recommended rate if the infusion is well tolerated.   
o Observations should be continued every 15 minutes until at least 30 minutes after the 
infusion has finished [14]. 
 
Recognition of HSRs to iv iron 
Acute HSRs to iron infusions, as to other iv drugs, are best classified as mild, moderate or 
severe/life-threatening (or anaphylactic) on the basis of symptoms, signs and clinical 
observations (Fig 1) [41,42].  Mild reactions can progress rapidly through moderate to severe 
ones; severe HSRs can also occur very rapidly without progression through the milder 
syndromes. 
 
A further mild acute adverse reaction has been described by Fishbane [43,44].  This occurs in 
about 1/100 patients given intravenous drugs and is characterized by transient flushing, joint 
pains and truncal myalgia. Its pathogenesis is unknown, but symptoms tend to abate 
spontaneously over a few minutes and do not usually recur on re-challenge. 
 
Management of HSRs to iv iron 
Management of an HSR to iv iron depends on its severity and is outlined in Fig 1; each step 
will not be detailed here, but in every instance of an HSR, the iron infusion should be stopped 
immediately and recommenced, after at least 15 minutes, only in patients with mild and 
spontaneously improved HSRs.  There is scanty formal evidence relating to management of 
HSRs occurring specifically during iron infusions and the recommendations made in Fig 1 are 
drawn from other contexts in which iv drugs are given [45-50]. 
 
The selection of individual drugs for treatment of HSRs, and their doses and routes of 
administration, varies according to local practice. However, it is worth noting that iv 
antihistamines are no longer favoured as their side effects (tachycardia, hypotension, 
somnolence) may mimic mild HSRs or make them appear more severe than they actually are 
[51] 
 
If an HSR occurs, it is important that after it has resolved it is carefully documented so that a 
future treatment strategy can be drawn up.  Factors that need to be recorded include the 
severity of the attack (mild, moderate, severe) and its course; any previous administration of 
iv iron preparations (including their dates, doses and infusion rates); identified risk factors; 
the interventions made and the response to them; whether the patient was discharged home or 
transferred to intensive care; and that the responsible clinician and the local drug regulatory 
authorities were informed of the event [48]. 
 
Conclusions 
Iron deficiency anemia is common world-wide, and its causes cross all medical specialties.  
Most patients respond well to treatment with oral iron preparations.  For those not doing so, 
and for those who are intolerant of oral iron or who are severely anemic, iv iron offers an 
excellent alternative, so long as it is given in the appropriate dose, in a safe clinical 
environment and with due recognition of the occasionally severe adverse reactions that it can 
evoke.   
 
Many people with iron deficiency anemia receive inappropriate, too little, or even no 
treatment for their condition; it is hoped that application of some of the points from this 
pragmatic review will help practitioners prescribe and administer the right treatment for their 
patients safely and effectively. 
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 Table 1.  Blood film and iron indices in iron deficiency anemia and anemia of chronic 
disease. 
 Normal range (precise 
values vary between 
laboratories) 
Iron 
deficiency 
anemia 
Anemia of chronic 
disease 
Serum iron 11-32 µmol/l Low Low  
Ferritin 22-560 pmol/l Low** Normal or raised 
Transferrin 1.88 – 3.41 g/L High Low 
Transferrin 
saturation 
20-50% Low Normal 
Total iron binding 
capacity 
45-82 µmol/l High Low or normal 
Red cell 
morphology 
MCV 80-95 fl 
MCHC 30-34 
gHb/100ml 
Microcytic,  
hypochromic * 
Normocytic or 
microcytic, 
normochromic 
*Microcytosis and hypochromasia can also be present in thalassaemia and sideroblastic 
anemia.  **Ferritin is an acute phase protein and can be raised in the presence of iron 
deficiency, for example in renal failure, hyperthyroidism, poorly controlled diabetes mellitus 
and inflammatory disease such as inflammatory bowel disease  
 
 Table 2. WHO definition of anemia (adapted from ref [2]) 
 
 
 
 
 
 
 
 
 
Age Hb (g/dl) 
Children (6 months – 5 
years) 
<11.0 
Children (5-11 years) <11.5 
Children (12-13 years) <12.0 
Pregnant women <11.0 
Non-pregnant women <12.0 
Men <13.0 
 Table 3.  Simplified method for estimating cumulative iron dose (adapted from ref [37]) 
Hb g/dl Body weight 35 kg to <70 kg Body weight ≥70 kg* 
<10 g/dl 1,500 mg 2,000 mg 
≥10 g/dl 1,000 mg 1,500 mg 
         
*ideal body weight is used in overweight patients, and actual weight in underweight people.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Outline of recognition and treatment of hypersensitivity reactions to iv iron 
(from ref [15] with permission) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient no better 
Transfer quickly to 
intensive care unit 
Mild HSR  
Itching, flushing, urticaria, 
sensation of heat,  slight 
chest tightness, 
hypertension,  
back/ joint pains  
Moderate HSR 
As in Mild reaction + transient 
cough, flushing, chest tightness,  
nausea, shortness of breath,   
urticaria, tachycardia, 
hypotension 
  
  
Severe/life-threatening HSR  
Sudden onset and rapid 
aggravation of symptoms  +  
wheezing/stridor,  periorbital 
edema,  cyanosis, loss of 
consciousness,  
cardiac/respiratory arrest 
Management 
Stop iron infusion for ≥15 mins 
Inform doctor 
Monitor pulse,  BP,  resp rate, 
O2 saturation 
Wait and watch  
Treat as for mild reaction AND  
Stop iron infusion 
Call doctor 
Consider volume load (eg iv 
0.9% saline 500ml), iv 
corticosteroid (eg  
hydrocortisone 200mg) 
Treat as in moderate reaction 
AND  
Call fast response team  
Stop iron infusion 
Adrenaline im (0.5mg 1/1000) 
or iv (0.1mg 1/10000)  
Nebulised Β2 agonist  
Further isotonic volume load  
iv corticosteroid 
O2 face mask 
ACLS (if necessary) 
Patient better 
Restart iron 
infusion at 
reduced rate 
(eg 50%) 
Patient no 
better in  
5-10 mins, or 
deteriorating 
Patient well 
Observe for ≥1-4 hr 
Document event                                  
Consider future   
treatment strategy 
 
Patient 
deteriorating 
Symptoms recur 
Stop iron infusion 
Manage as above 
Document event 
 Figure 2.  Algorithm for management of iron deficiency anemia    
 
 
 
 
 
 
 
 
 
IRON DEFICIENCY 
 
Identify and treat cause 
Severe/symptomatic IDA 
Malabsorption                  
Active inflammatory disease 
Oral iron tolerated 
Check Hb, transferrin 
saturation, ferritin after 2-3 
months 
Hb and iron indices normal 
Check on 
adherence; 
consider iv 
iron 
Continue oral 
iron for 3 
months 
Check Hb and iron 
indices periodically 
depending on 
cause of IDA 
Hb and iron 
indices normal 
No further 
action 
Reconsider cause of IDA 
Restart oral iron (see above) 
no 
no 
no 
no 
no 
no 
yes 
yes 
yes 
yes 
yes 
yes 
Reconsider cause of IDA 
and give further iv iron  
oral 
iron 
iv 
iron 
oral 
iron 
oral 
iron 
iv 
iron 
iv 
iron 
